Abstract:Objectives: Decades ago, we developed adjuvant chemotherapy of three steps (ACTS) in advanced ovarian cancer, of which the first step is first-line platinum–taxane chemotherapy for six cycles, the second step is cyclophosphamide-etoposide per four weeks for six cycles, the third step is cyclophosphamide-platinum per eight weeks for six cycles. Here, we aimed investigate the efficacy and safety of ACTS in advanced ovarian cancer by randomized controlled trial. Methods: We conducted a randomized, open-label, controlled single center phase 2 trial. Eligible patients had newly diagnosed, advanced (FIGO2014 stage IIIc/IV), high-grade ovarian cancer and were having a complete response after optimal cytoreductory surgery and first-line platinum–taxane chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive step 2 and 3 of ACTS (ACTS group, step 2: cyclophosphamide 0.4g d1-d3 IV + etoposide 0.1g d1-d3 IV per 4 weeks for six cycles; step 3: cyclophosphamide 0.6g d1-d2 IV + carboplatin AUC=5 d1 IV per 8 weeks for 6 cycles) or no treatment (control group). The primary endpoint was overall survival, the secondary endpoints were progression-free survival and safety. Results: Of the 130 patients who underwent randomization, 65 were assgined to ACTS group. In the interim analysis, the median progression-free survival was significantly longer in the ACTS group than in the control group (22.0 months vs. 9.53 months; hazard ratio for disease progression or death, 0.559; 95% confidence interval [CI], 0.368-0.849; P=0.006, Fig.1). In the interim analysis of overall survival (performed after the deaths of 15 of 130 patients [11.8%] in the overall population), the estimated Kaplan–Meier probability of survival at 36 months was 90.7% in the ACTS group and 79.0% in the control group (hazard ratio for death, 0.42; 95% CI, 0.146 to 1.21). The most common adverse events of grade 3 or higher were neutropenia (in 62.7%), and thrombocytopenia (in 11.9%). No treatment-related deaths occurred. Conclusions: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received adjuvant chemotherapy of three steps (ACTS) had significantly longer progression-free survival than those who didn't. (ClinicalTrials., NCT02562365.). Decades ago, we developed adjuvant chemotherapy of three steps (ACTS) in advanced ovarian cancer, of which the first step is first-line platinum–taxane chemotherapy for six cycles, the second step is cyclophosphamide-etoposide per four weeks for six cycles, the third step is cyclophosphamide-platinum per eight weeks for six cycles. Here, we aimed investigate the efficacy and safety of ACTS in advanced ovarian cancer by randomized controlled trial. We conducted a randomized, open-label, controlled single center phase 2 trial. Eligible patients had newly diagnosed, advanced (FIGO2014 stage IIIc/IV), high-grade ovarian cancer and were having a complete response after optimal cytoreductory surgery and first-line platinum–taxane chemotherapy. Patients were randomly assigned in a 1:1 ratio to receive step 2 and 3 of ACTS (ACTS group, step 2: cyclophosphamide 0.4g d1-d3 IV + etoposide 0.1g d1-d3 IV per 4 weeks for six cycles; step 3: cyclophosphamide 0.6g d1-d2 IV + carboplatin AUC=5 d1 IV per 8 weeks for 6 cycles) or no treatment (control group). The primary endpoint was overall survival, the secondary endpoints were progression-free survival and safety. Of the 130 patients who underwent randomization, 65 were assgined to ACTS group. In the interim analysis, the median progression-free survival was significantly longer in the ACTS group than in the control group (22.0 months vs. 9.53 months; hazard ratio for disease progression or death, 0.559; 95% confidence interval [CI], 0.368-0.849; P=0.006, Fig.1). In the interim analysis of overall survival (performed after the deaths of 15 of 130 patients [11.8%] in the overall population), the estimated Kaplan–Meier probability of survival at 36 months was 90.7% in the ACTS group and 79.0% in the control group (hazard ratio for death, 0.42; 95% CI, 0.146 to 1.21). The most common adverse events of grade 3 or higher were neutropenia (in 62.7%), and thrombocytopenia (in 11.9%). No treatment-related deaths occurred. Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received adjuvant chemotherapy of three steps (ACTS) had significantly longer progression-free survival than those who didn't. (ClinicalTrials., NCT02562365.).

Three-step chemotherapy after primary debulking surgery in 15 patients with stage Ⅲc or Ⅳovarian cancer

Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases

Clinical Outcomes and Prognostic Factors of Patients with Epithelial Ovarian Cancer Subjected to First-Line Treatment: a Retrospective Study of 251 Cases

Modified Intraperitoneal Chemotherapy Without Bevacizumab As a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

[A Multicenter Randomized Clinical Trial of Weekly Paclitaxel and Carboplatin Vs Three Weeks Paclitaxel and Carboplatin As First Line Chemotherapy in Epithelial Ovarian Cancer].

Analysis of Factors Related to the Prognostic Benefit of Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery in Patients with Advanced Ovarian Cancer

Intraperitoneal chemotherapy combined with intravenous chemotherapy after operation in the ovarian epithelial cancer

What Influences the Long-Term Survival of Advanced High-Grade Serous Ovarian Cancer?

Combination treatment and its efficacy on epithelial ovarian carcinoma

Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study

Combined treatment and prognostic analysis of advanced epithelial ovarian carcinoma]

Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?

Dose-Dense Early Postoperative Intraperitoneal Chemotherapy In Ovarian Cancer: Randomized, Phase Ii Trial.

Docetaxel Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy and Hyperthermia in the Treatment of Advanced Ovarian Cancer.

CYTOREDUCTIVE SURGERY PLUS HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY IMPROVES SURVIVAL IN PATIENTS WITH STAGE IIIC OVARIAN CANCER

Adjuvant Chemotherapy of Three Steps (ACTS) in Patients with Newly Diagnosed Advanced Ovarian Cancer: Interim Analysis of a Randomized Phase II Trial

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study

Primary or interval debulking surgery for stage IV ovarian cancer patients: experience from a ten-year case series

Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial

Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer